Top

Current Hematologic Malignancy Reports

Published in:

01-02-2018 | T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)

The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL)

Authors: Helen Ma, Ardy Davarifar, Jennifer E. Amengual

Published in: Current Hematologic Malignancy Reports | Issue 1/2018

Abstract

Purpose of Review

Peripheral T cell lymphoma is a rare heterogeneous group of diseases which are characterized by poor outcomes to treatment and short overall survival. In the past decade, several new therapies targeting T cell biology have been approved in the relapsed setting. These new therapies, such as pralatrexate, romidepsin, belinostat, and brentuximab vedotin, have begun to make their way into practice. Despite these advances, outcomes have not changed dramatically. In recent years, efforts have been made to incorporate these new therapies into combination strategies to treat this challenging disease entity. Herein we will review some of the latest developments.

Recent Findings

With the new WHO classification, discrete entities of PTCL are now being identified by molecular and phenotypic markers. This new classification is critical to our ability to define disease entities which may respond to certain classes of targeted therapy. Some such mutations include genes controlling epigenetics (TET2, IDH2, DNMT3A, RHOA, CD28). As such, epigenetic therapies such as histone deacetylase (HDAC) inhibitors have become the platform to which other novel therapies or chemotherapy has been added. Early phase clinical studies have demonstrated that combination therapy with romidepsin plus other agents known to have activity in T cell lymphoma have enhanced clinical benefit for this group of diseases. In addition, the antibody drug conjugate, brentuximab vedotin has been shown to have potent activity in T cell lymphomas expressing CD30. This drug is being studied as well with other targeted therapies and chemotherapy in an effort to improve response rates and progression-free survival.

Summary

Although T cell lymphomas remain a highly challenging group of diseases to treat, new efforts to leverage drugs that discretely target the biology that drives T cell lymphomagenesis in combination provide hope that improved outcomes may be realized in the near future.

•• Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90. https://doi.org/10.1182/blood-2016-01-643569. With the new WHO classification, discrete entities of PTCL are now being identified by molecular and phenotypic markers. This new classification is critical to our ability to define disease entities which may respond to certain classes of targeted therapy.CrossRefPubMedPubMedCentral

Foss F. T-cell lymphomas. New York: Humana Press; 2012.

Vose J, Armitage J, Weisenburger D, International, T. C. L. P. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30. https://doi.org/10.1200/JCO.2008.16.4558.CrossRefPubMed

Durkop H, et al. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin’s disease. Cell. 1992;68(3):421–7. https://doi.org/10.1016/0092-8674(92)90180-K.CrossRefPubMed

Morris SW, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science. 1994;263(5151):1281–4. https://doi.org/10.1126/science.8122112.CrossRefPubMed

Dupuis J, Boye K, Martin N, Copie-Bergman C, Plonquet A, Fabiani B, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol. 2006;30(4):490–4. https://doi.org/10.1097/00000478-200604000-00009.CrossRefPubMed

de Leval L, Rickman DS, Thielen C, Reynies A, Huang YL, Delsol G, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood. 2007;109(11):4952–63. https://doi.org/10.1182/blood-2006-10-055145.CrossRefPubMed

Muto H, Sakata-Yanagimoto M, Nagae G, Shiozawa Y, Miyake Y, Yoshida K, et al. Reduced TET2 function leads to T-cell lymphoma with follicular helper T-cell-like features in mice. Blood Cancer J. 2014;4(12):e264. https://doi.org/10.1038/bcj.2014.83.CrossRefPubMedPubMedCentral

Matsumoto Y, Horiike S, Ohshiro M, Yamamoto M, Sasaki N, Tsutsumi Y, et al. Expression of master regulators of helper T-cell differentiation in peripheral T-cell lymphoma, not otherwise specified, by immunohistochemical analysis. Am J Clin Pathol. 2010;133(2):281–90. https://doi.org/10.1309/AJCP0SBHYVLY5EML.CrossRefPubMed

10.

Yamada Y. Phenotypic and functional analysis of leukemic cells from 16 patients with adult T-cell leukemia/lymphoma. Blood. 1983;61(1):192–9.PubMed

11.

Karube K, Ohshima K, Tsuchiya T, Yamaguchi T, Kawano R, Suzumiya J, et al. Expression of FoxP3, a key molecule in CD4CD25 regulatory T cells, in adult T-cell leukaemia/lymphoma cells. Br J Haematol. 2004;126(1):81–4. https://doi.org/10.1111/j.1365-2141.2004.04999.x.CrossRefPubMed

12.

Karube K, Aoki R, Sugita Y, Yoshida S, Nomura Y, Shimizu K, et al. The relationship of FOXP3 expression and clinicopathological characteristics in adult T-cell leukemia/lymphoma. Mod Pathol. 2008;21(5):617–25. https://doi.org/10.1038/modpathol.2008.25.CrossRefPubMed

13.

Barbi J, Pardoll DM, Pan F. Ubiquitin-dependent regulation of Foxp3 and Treg function. Immunol Rev. 2015;266(1):27–45. https://doi.org/10.1111/imr.12312.CrossRefPubMedPubMedCentral

14.

Lue JK, Kress A, Amengual JE. Therapeutic options for aggressive T-cell lymphomas. Curr Hematol Malig Rep. 2017;12(4):269–81. https://doi.org/10.1007/s11899-017-0389-7.CrossRefPubMed

15.

Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, et al. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer. 2017;123(7):1174–83. https://doi.org/10.1002/cncr.30416.CrossRefPubMed

16.

• Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970–6. https://doi.org/10.1200/JCO.2012.44.7524. Survival for patients with relapsed PTCL is dismal and highlights the need for improved therapies.CrossRefPubMed

17.

Quivoron C, Couronné L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. 2011;20(1):25–38. https://doi.org/10.1016/j.ccr.2011.06.003.CrossRefPubMed

18.

Mercher T, Quivoron C, Couronné L, Bastard C, Vainchenker W, Bernard OA. TET2, a tumor suppressor in hematological disorders. Biochim Biophys Acta. 2012;1825(2):173–7. https://doi.org/10.1016/j.bbcan.2011.12.002.PubMed

19.

Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med. 2012;366(1):95–6. https://doi.org/10.1056/NEJMc1111708.CrossRefPubMed

20.

Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012;119(8):1901–3. https://doi.org/10.1182/blood-2011-11-391748.CrossRefPubMedPubMedCentral

21.

Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117(22):5827–34. https://doi.org/10.1182/blood-2010-10-312603.CrossRefPubMedPubMedCentral

22.

Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631–6. https://doi.org/10.1200/jco.2011.37.4223.CrossRefPubMed

23.

O’Connor OA, Horwitz S, Masszi T, van Hoof A, Brown P, Doorduijn J, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33(23):2492–9. https://doi.org/10.1200/jco.2014.59.2782.CrossRefPubMedPubMedCentral

24.

Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012;69(4):901–9. https://doi.org/10.1007/s00280-011-1766-x.CrossRefPubMed

25.

Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26(8):1766–71. https://doi.org/10.1093/annonc/mdv237.CrossRefPubMed

26.

Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(21):3109–15. https://doi.org/10.1200/JCO.2006.10.2434.CrossRefPubMed

27.

Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res. 2008;14(14):4500–10. https://doi.org/10.1158/1078-0432.CCR-07-4262.CrossRefPubMed

28.

Ocio EM, Vilanova D, Atadja P, Maiso P, Crusoe E, Fernandez-Lazaro D, et al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica. 2010;95(5):794–803. https://doi.org/10.3324/haematol.2009.015495.CrossRefPubMed

29.

San-Miguel JF, Hungria VTM, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195–206. https://doi.org/10.1016/s1470-2045(14)70440-1.CrossRefPubMed

30.

• Amengual JE, Lichtenstein R, Lue J, Sawas A, Deng C, Lichtenstein E, Khan K, Atkins L, Rada A, Kim HA, Chiuzan C, Kalac M, Marchi E, Falchi L, Francescone MA, Schwartz L, Cremers S, O’Connor OA. A phase I study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma. Blood. 2017;blood-2017-09-806737 https://doi.org/10.1182/blood-2017-09-806737. Combination of the first two approved drugs in PTCL lymphoma is well tolerated and leads to a high rate of response.

31.

Moskowitz AJKR, Mehta-Shah N, Myskowski P, Kheterpal M, Dogan A, Davey T, Galassa N, Evan M, Shah M, Ganesan N, Lubin L, Kim YH, Khodadoust M, Almazan T, Dai J, Jacobsen ED, Weinstock DM, Horwitz SM. In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-δ,γ inhibitor, in combination with romidepsin or bortezomib in relapsed/refractory T-cell lymphoma. 2017.

32.

Strati POY, Fayad LE, Nastoupil L, Fowler NH, Hagemeister FB, Kwak LW, Lee HJ, Wang, W, Westin JR, Ruben C, Wesson E, Fanale MA. A Phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas. 2017.

33.

O’Connor OAL, J. K, Amengual JE, Sawas A, Deng C, Lichtenstein E, et al. Oral azacytadine (AZA) and romidepsin (R) reveals promising activity in patients with relapsed or refractory (R/R) periphearl T-cell lymphoma (PTCL). Hematol Oncol. 2017;35:274–5. https://doi.org/10.1002/hon.2438_147.CrossRef

34.

Xu WZ,H, Wang L, Liang J, Kong Y, Wu W, Fan L, et al. The efficacy and tolerance of chidamide, prednisone, cyclophosphamide and thalidomide (C-PCT) in relapsed or refractory peripheral T-cell lymphoma: a pilot study. Hematol Oncol. 2017;35:397. https://doi.org/10.1002/hon.2439_167.CrossRef

35.

Hopfinger G, Nösslinger T, Lang A, Linkesch W, Melchardt T, Weiss L, et al. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Ann Hematol. 2014;93(3):459–62. https://doi.org/10.1007/s00277-014-2009-0.CrossRefPubMed

36.

Mehta-Shah N, et al. A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: activity in T-cell lymphoma. J Clin Oncol. 2015;33:8521. https://doi.org/10.1200/jco.2015.33.15_suppl.8521.

37.

Mehta-Shah N, et al. A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B- and T-cell lymphomas. Blood. 2017;130:821.

38.

Tan D, Phipps C, Hwang WY, Tan SY, Yeap CH, Chan YH, et al. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. Lancet Haematol. 2015;2(8):e326–33. https://doi.org/10.1016/S2352-3026(15)00097-6.CrossRefPubMed

39.

O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29(9):1182–9. https://doi.org/10.1200/JCO.2010.29.9024.CrossRefPubMedPubMedCentral

40.

Jain S, Jirau-Serrano X, Zullo KM, Scotto L, Palermo CF, Sastra SA, et al. Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma. Clin Cancer Res. 2015;21(9):2096–106. https://doi.org/10.1158/1078-0432.ccr-14-2249.CrossRefPubMed

41.

Delarue R, Dupuis J, Sujobert P, Barbieux S, Marçais A, Tournilhac O, et al. Treatment with hypomethylating agent 5-azacytidine induces sustained response in angioimmunoblastic T cell lymphomas. Blood. 2016;128:4164.

42.

Marchi E, Zullo KM, Amengual JE, Kalac M, Bongero D, McIntosh CM, et al. The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma. Br J Haematol. 2015;171(2):215–26. https://doi.org/10.1111/bjh.13566.CrossRef

43.

Kanagal-Shamanna R, Lehman NL, O’Donnell JP, Lim MS, Schultz DS, Chitale DA, et al. Differential expression of aurora-A kinase in T-cell lymphomas. Mod Pathol. 2013;26(5):640–7. https://doi.org/10.1038/modpathol.2012.211.CrossRefPubMedPubMedCentral

44.

Zullo KM, Guo Y, Cooke L, Jirau-Serrano X, Mangone M, Scotto L, et al. Aurora A kinase inhibition selectively synergizes with histone deacetylase inhibitor through cytokinesis failure in T-cell lymphoma. Clin Cancer Res. 2015;21(18):4097–109. https://doi.org/10.1158/1078-0432.CCR-15-0033.CrossRefPubMedPubMedCentral

45.

Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, et al. Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108. J Clin Oncol. 2015;33(21):2399–404. https://doi.org/10.1200/JCO.2014.60.6327.CrossRefPubMedPubMedCentral

46.

O’Connor OAOM, Jacobsen ED, Vidal JMR, Trotman J, Demeter J, Masszi T, Prereira J, Ramchandren R, d’AMore FA, Foss F, Kim WS, Leonard JP, Chiattone CS, Zinzani PL, Liu H, Jung JA, Zhou X, et al. First multicenter, randomized phase 3 study in patients (Pts) with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL): alisertib (MLN8237) versus investigator’s choice (Lumiere trial; NCT01482962). 2015.

47.

O’Connor OAOM, Jacobsen ED, Vidal JMR, Trotman J, Demeter J, Masszi T, et al. First multicenter, randomized phase 3 study in patients (pts) with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL): alisertib (MLN8237) versus investigator’s choice (Lumiere trial; NCT01482962). Blood. 2015;126:341.

48.

Park JH, Jong HS, Kim SG, Jung Y, Lee KW, Lee JH, et al. Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating aurora-A kinase. J Mol Med (Berl). 2008;86(1):117–28. https://doi.org/10.1007/s00109-007-0260-8.CrossRef

49.

DeAngelo DJ, Spencer A, Bhalla KN, Prince HM, Fischer T, Kindler T, et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 2013;27(8):1628–36. https://doi.org/10.1038/leu.2013.38.CrossRefPubMed

50.

Zinzani PL, Musuraca G, Tani M, Stefoni V, Marchi E, Fina M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007;25(27):4293–7. https://doi.org/10.1200/JCO.2007.11.4207.CrossRefPubMed

51.

Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, et al. Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. Leuk Lymphoma. 2016;57(3):635–43. https://doi.org/10.3109/10428194.2015.1075019.CrossRefPubMed

52.

Horwitz SP,P, Flinn I, Kahl BS, Sweeney J, Stern HM, Douglas M, et al. Duvelisib (IPI-145), a phosphoinositide-3-kinase-δ,γ inhibitor, shows activity in patients with relapsed/refractory T-cell lymphoma. Blood. 2014;124:803.CrossRef

53.

Moskowitz AJ, et al. In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-δ, γ inhibitor, in combination with romidepsin or bortezomib in relapsed/refractory T-cell lymphoma. Blood. 2017;130:819.CrossRef

54.

Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343(6168):305–9. https://doi.org/10.1126/science.1244917.CrossRefPubMed

55.

Toumishey E, Prasad A, Dueck G, Chua N, Finch D, Johnston J, et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer. 2015;121(5):716–23. https://doi.org/10.1002/cncr.29103.CrossRefPubMed

56.

Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer. 2013;49(13):2869–76. https://doi.org/10.1016/j.ejca.2013.04.029.CrossRefPubMed

57.

Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia/lymphoma: ATLL-002. J Clin Oncol. 2016;34(34):4086–93. https://doi.org/10.1200/JCO.2016.67.7732.CrossRefPubMed

58.

Cosenza M, et al. The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines. Cancer Biol Ther. 2016;1–13. https://doi.org/10.1080/15384047.2016.1219820.

59.

Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30(18):2190–6. https://doi.org/10.1200/JCO.2011.38.0402.CrossRefPubMed

60.

Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017:blood-2017-05-780049. https://doi.org/10.1182/blood-2017-05-780049.

61.

Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O’Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014;123(20):3095–100. https://doi.org/10.1182/blood-2013-12-542142.CrossRefPubMedPubMedCentral

62.

Ward JPT,J, Luo J, Wagner-Johnston ND, Cashen AF, Fehniger TA, Bartlett NL. A phase I trial of brentuximab vedotin in combination with lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. Blood. 2015;126:3988.

63.

Ghobrial IM, Siegel DS, Vij R, Berdeja JG, Richardson PG, Neuwirth R, et al. TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: a phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenstrom’s macroglobulinemia. Am J Hematol. 2016;91(4):400–5. https://doi.org/10.1002/ajh.24300.CrossRefPubMed

64.

Lunning MH,S, Mehta-Shah M, Moskowitz A, Advani R, Beaven A, Haverkos B, et al. Phase I/II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell non-Hodgkin lymphoma: phase I results from the T-cell consortium. Hematol Oncol. 2017;35:411–2. https://doi.org/10.1002/hon.2439_190.CrossRef

65.

Safar VDLL, Meignan M, Bachy E, Cartron G, Moles-Moreau MP, Delmer A, Bouabdallah R, Voillat L, Corront B, Casasnovas O, Cacheux V, Gressin R, Robreau Y, Pallardy S, Tilly H, Delfau-Larue MH, Gaulard P, Haioun C. Prospective phase II trial of lenalidomide in association with CHOP in elderly patients with angioimmunoblastic T cell lymphoma (AITL): interim analysis of a LYSA study. 2015.

66.

Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, et al. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. Br J Haematol. 2016;172(4):535–44. https://doi.org/10.1111/bjh.13855.CrossRefPubMed

67.

Kim SJ, Shin DY, Kim JS, Yoon DH, Lee WS, Lee H, et al. A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas. Ann Oncol. 2016;27(4):712–8. https://doi.org/10.1093/annonc/mdv624.CrossRefPubMed

68.

Dupuis JM,F, Ghesquieres H, Tilly H, Casasnovas O, Amorim S, Ribrag V, et al. Final analysis of the RO-CHOP phase Ib/II study: romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL). Blood. 2014;124:504.

69.

Horwitz SSAR, Forero-Torres A, Bartlett NL, Advani R, Pro B, Chen R, Davies AJ, Illidge T, Huebner D, Kennedy DA, Fanale MA. Frontline treatment of CD30+ peripheral T-cell lymphomas with brentuximab vedotin in combination with CHP: 3-year durability and survival follow-up. 2015.

70.

Shustov A, et al. Pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in previously untreated patients with peripheral T-cell lymphoma (PTCL): a phase 1 dose-escalation study. Blood. 2017;130:818.

71.

Witzig TE, Reeder C, Han JJ, LaPlant B, Stenson M, Tun HW, et al. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood. 2015;126(3):328–35. https://doi.org/10.1182/blood-2015-02-629543.CrossRefPubMedPubMedCentral

72.

Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, et al. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014;32(28):3137–43. https://doi.org/10.1200/JCO.2013.54.2456.CrossRefPubMedPubMedCentral

73.

Tashiro H, Brenner MK. Immunotherapy against cancer-related viruses. Cell Res. 2017;27(1):59–73. https://doi.org/10.1038/cr.2016.153.CrossRefPubMed

74.

Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698–704. https://doi.org/10.1200/JCO.2015.65.9789.CrossRefPubMedPubMedCentral

75.

Kwong YL, Chan TSY, Tan D, Kim SJ, Poon LM, Mow B, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017;129(17):2437–42. https://doi.org/10.1182/blood-2016-12-756841.CrossRefPubMed

Title: The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL)
Authors: Helen Ma
Ardy Davarifar
Jennifer E. Amengual
Publication date: 01-02-2018
Publisher: Springer US
Published in: Current Hematologic Malignancy Reports / Issue 1/2018
Print ISSN: 1558-8211
Electronic ISSN: 1558-822X
DOI: https://doi.org/10.1007/s11899-018-0432-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The Future of Combination Therapies for Peripheral T Cell Lymphoma (PTCL)

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2018

Updates of Peripheral T Cell Lymphomas Based on the 2017 WHO Classification

Immunologic Milieu of Mature T-Cell and NK-Cell Lymphomas—Implications for Therapy

Rethinking Antimicrobial Prophylaxis in the Transplant Patient in the World of Emerging Resistant Organisms—Where Are We Today?

Twitter Use in the Hematopoietic Cell Transplantation Community

NK/T Cell Lymphoma: Updates in Therapy

Biomarkers in Graft-Versus-Host Disease: from Prediction and Diagnosis to Insights into Complex Graft/Host Interactions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page